Nazione: Svizzera
Lingua: italiano
Fonte: Swissmedic (Swiss Agency for Therapeutic Products)
rifampicinum, clofaziminum, dapsonum
Novartis Pharma Schweiz AG
J04BA
rifampicinum, clofaziminum, dapsonum
Capsule e Compresse
I) Rifampicin 150 mg, Kapseln: rifampicinum 150 mg, calcii stearas, lactosum 25 mg, Kapselhülle: gelatina, E 172 (rubrum), E 171, Drucktinte: lacca, E 172 (nigrum), propylenglycolum, aqua purificata, pro capsula. II) Rifampicin 300 mg, Kapseln: rifampicinum 300 mg, calcii stearas, lactosum 50 mg, Kapselhülle: gelatina, E 171, E 172 (rubrum), E 172 (flavum), E 172 (nigrum), Drucktinte: lacca, E 172 (nigrum), propylenglycolum, aqua purificata, pro capsula. III) Clofazimine 50 mg, Weichgelatinekapseln: clofaziminum 50 mg, acidum citricum, propylenglycolum, rapae oleum raffinatum, lecithinum ex soja, cera alba, sojae oleum hydrogenatum 1.17 mg, oleum vegetabile partim hydrogenatum, Kapselhülle: gelatina, glycerolum (85 per centum), 4-methoxyacetophenonum, ethylvanillinum, E 172 (nigrum), E 172 (rubrum), E 321, E 215 0.23 mg, propylis parahydroxybenzoas natricus 0.11 mg, pro capsula. IV) Dapson 50 mg, Tabletten: dapsonum 50 mg, lactosum monohydricum 8 mg, maydis amylum, amylum pregelificatum, natrii laurilsulfas corresp. natrium 0.0025 mg, acidum stearicum, magnesii stearas, pro compresso.
A
Synthetika
La lebbra
zugelassen
2011-12-15